Latham & Watkins Advises Abridge in US$250 Million Series D Funding Round

Abridge, the leading generative AI platform for clinical conversations, announced it has raised US$250 million in a Series D investment, coinciding with the milestone of surpassing 100 deployments at some of the largest and most complex health systems in the United States. The Series D investment, co-led by Elad Gil and IVP, includes contributions from Bessemer Venture Partners, California Health Care Foundation, CapitalG, CVS Health Ventures, K. Ventures, Lightspeed Venture Partners, NVentures (NVIDIA’s venture capital arm), Redpoint Ventures, Spark Capital, and SV Angel. The investment will fuel additional development of AI capabilities and commercial growth to support broader applications.

Latham & Watkins LLP represents Abridge in the transaction with a corporate deal team led by Bay Area partner Brian Patterson, with associates Ed Grigoryan, Saem Kim, and Emma Mayberry.